

Synthesis, and biological screening of chloropyrazine conjugated benzothiazepine derivatives as potential antimicrobial, antitubercular and cytotoxic agents

Afzal B. Shaik^{1,*}, Richie R. Bhandare^{2*}, Srinath Nissankararao³, Bontha Venkata Subrahmanya Lokesh⁴, Shaik Shahanaaz⁵, M. Mukhlesur Rahman^{6,*}

¹Department of Pharmaceutical Chemistry, Vignan Pharmacy College, Jawaharlal Nehru Technological University, Vadlamudi-522213, Andhra Pradesh, India.
<https://orcid.org/0000-0002-9036-1963>

^{2*}Department of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, Ajman University, Ajman PO Box 346, UAE. <https://orcid.org/0000-0003-1221-3962>

³Montvale, New Jersey, NJ 07645, USA; srinath.n2k@gmail.com;
<https://orcid.org/0000-0002-8678-6352>

⁴Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia.
lokeshb@ucsiuniversity.edu.my

⁵Department of Pharmaceutical Chemistry, Victoria College of Pharmacy, Nallapadu-522001, Guntur District, Andhra Pradesh, India;
shahanaazchemistry@gmail.com; shahanaazpharmacy@gmail.com;
<https://orcid.org/0000-0001-9692-8468>

⁶Medicines Research Group, School of Health, Sports and Bioscience, University of East London, Stratford Campus, Water Lane, London E 15 4LZ; m.rahman@uel.ac.uk;
<http://orcid.org/0000-0001-8180-7970>

*Correspondence: bashafoye@gmail.com (A.B.S); r.bhandareh@ajman.ac.ae (R.R.B); m.rahman@uel.ac.uk (M.M.R)

Tel.: +91-9966014374 (A.B.S); +971-565646655 (R.R.B); +44-7578022845 (MMR).

Abstract

A series of twenty new chloropyrazine conjugated benzothiazepines (**22-41**) have been synthesized with 58%–95% yields. The compounds were characterized by using different spectroscopic techniques including FT-IR, ^1H NMR, ^{13}C NMR spectroscopy and mass spectrometry. The synthesized compounds (**22-41**) and their precursor chalcones (**2-21**) were evaluated for antitubercular and cytotoxic activities. Additionally, compounds **22-41** were also tested for antimicrobial activity. Among the chalcone series (**2-21**), compounds **7** and **14** showed significant antitubercular activities (MICs 25.51 and 23.89 μM , respectively), whereas among benzothiazepines (**22-41**), compounds **27** and **34** displayed significant antimicrobial (MICs 38.02 μM , 19.01 μM) and antitubercular (MIC 18.10 μM) activities. Compounds **7** and **41** displayed cytotoxic activities with IC_{50} of 46.03 ± 1 and 35.10 ± 2 μM respectively. All the compounds were evaluated for cytotoxic activity on normal human liver cell lines (L02) and found to be relatively less selective towards this cell line. The most active compounds identified through this study could be considered as potential leads for the development of drugs with possible antimicrobial, antitubercular, and cytotoxic activities.

Keywords: chloropyrazine, benzothiazepines, antitubercular, antimicrobial, cytotoxic

1. Introduction

Heterocyclic compounds play a vital role in the design and development of drugs against different diseases. More than seventy percent of drugs used in therapy contain one or more heterocyclic rings. Out of the 24 small drug molecules approved in 2020 by Food and Drug Administration (FDA), USA, 22 drugs contain heterocyclic rings. Similarly, of the 10 top drugs prescribed in USA, six drugs contain heterocyclic rings. This scenario is due to the property of the heterocyclic rings to serve as useful templates to modulate physicochemical properties of the drug molecules including the hydrogen bond capacity, polarity, and lipophilicity. Presence of hetero atoms or heterocyclic nucleus within the molecules may further improve pharmacokinetic, pharmacodynamic, and toxicological profiles of the drug candidates and finally drug molecules (Gomtsyan, 2012). Some of the heterocyclic rings are considered as privileged because of their significant drug-like properties. Medicinal chemists usually club or conjugate two or more such privileged heterocycles to create biologically useful molecules as a part of drug discovery programs. In the recent past, the design and synthesis of heterocyclic hybrids have received greater attention due to their ease of synthesis and improved biological properties. The structures that evolve from such conjugation are usually rigid frameworks that can show the appended rings in a well-defined fashion that is necessary for molecular recognition of the biological target. Usually, the variable nature of these functionalities defines the selectivity on a privileged core for a particular target.

Pyrazine and 1,5-benzothiazepine rings are two privileged aromatic heterocycles of interest to organic and medicinal chemists because of their ease of synthesis and biological activities. Both these scaffolds are prominent in a variety of drugs used in the treatment of different complications. For example, pyrazine ring is found in drugs like pyrazinamide (PZA) and morinamide (antitubercular), favipiravir (anti-corona viral), glipizide (antidiabetic), amiloride and benzamil (diuretic), acipimox (antihyperlipidemic), and bortezomib (multiple myeloma). 1,5-benzothiazepine scaffold is present in calcium channel blockers for cardiovascular problems- Diltiazem and Clentiazem (Nagao et al., 1972, Chaffman and Brogden, 1985), atypical antipsychotic agents- Quetiapine and Clotiapine, and the

antidepressant drug- Thiazesim (Kawakita et al., 1991, Geyer III et al., 1970, Hopenwasser et al., 2004) (Fig. 1).




Figure 1. Representative structures of clinically used pyrazine and benzothiazepine ring containing drugs.

Pyrazine derivatives were reported to possess excellent antitubercular (AmbroŹkiewicz et al., 2020, Bouz et al., 2020, Zitko et al., 2018, Miniyar et al., 2017, Zitko et al., 2016, Servusova-Vanaskova et al., 2015, Servusová et al., 2013, Zitko et al., 2013, Mangrolia and Osborne, 2020), anticancer (De Wang et al., 2020, Tantawy et al., 2020, Etaiw et al., Seo et al., 2020, Mamedova et al., 2019, Patil et al., 2019, Bhaskar et al., 2020), antimicrobial (Singh et al., 2020, Kuceroval-Chlupacova et al., 2016, Kuceroval-Chlupacova et al., 2015, Stepanić et al., 2019, Kuceroval-Chlupacova et al., 2018), antioxidant (Cavalier et al., 2001, Zaki et al., 2018, Abu-Hashem and El-Shazly, 2018), analgesic and anti-inflammatory (Shankar et al., 2017, Aneesa et al., 2015, Bills et al., 1939, Bariwal et al., 2008), and anti-pellagra activities (El-Bayouki, 2011). Many authors have reviewed the synthesis, characterization, and applications of benzothiazepines (Deshmukh et al., 2016, Saha et al., 2015, El-Bayouki, 2013, Sekhar, 2014, Shaik et al., 2020, Wu et al., 2017). This ring derivatives have shown promising anticancer (Gudisela et al., 2017, Ameta et al., 2012, Arya and Dandia, 2008, Ansari et al., 2008, Sharma et al., 1997, Upadhyay et al., 2012, Wang et al., 2020), antitubercular (Kendre et al., 2019), antibacterial and antifungal (Yan et al., 2019,

Tongxiu et al., 2018, Pant et al., 2018, Mor et al., 2017, B Patel et al., 2016, Li et al., 2017, El-Bayouki, 2013), antiviral (Di Santo and Costi, 2005, Kishor et al., 2017, Lokesh et al., 2017) activities. Representative structures of important pyrazine and benzothiazepine derivatives with potential antimycobacterial, antimicrobial, and anticancer activities are displayed below (Fig. 2).




Figure 2. Structures of selected pyrazine and 1,5-benzothiazepine derivatives with potent antimicrobial, antitubercular and anticancer activities.

In continuation for our interest in the synthesis and screening of heteroaryl chalcones (Shaik et al., 2020, Lokesh et al., 2019) and conjugated heterocycles (Palleapati et al., 2019, Lokesh et al., 2019, Yazdan et al., 2015) as well as the potential bioactivities of conjugated heterocyclic derivatives, we prepared and screened novel chloropyrazine conjugated 1,5-benzothiazepine derivatives. Both pyrazine and 1,5-benzothiazepine rings exhibited promising antimicrobial, antitubercular and cytotoxic activities as discussed above. Hence, the molecules synthesized for our study were expected to possess collective effect on the proposed activities. We have previously described the antibacterial & antifungal activities of chloropyrazine chalcones (**2-21**) [Vegesna et al., 2017]. Herein, we reported the synthesis of twenty new chloropyrazine conjugated benzothiazepines (**22-41**) as well as the antitubercular and cytotoxic activities of precursor chalcones (**2-21**), antimicrobial, antitubercular, and

cytotoxic activities of chloropyrazine conjugated 1,5-benzothiazepine derivatives (**22-41**). The general structures of the chloropyrazine chalcones and chloropyrazine conjugated 1,5-benzothiazepines are portrayed in Fig. 3.




Figure 3. General structures of 2-acetyl-5-chloropyrazine chalcones and chloropyrazine conjugated 1,5-benzothiazepine derivatives

2. Materials and methods

2.1. General

All solvents and reagents were obtained from S.D. Fine. Ltd. Mumbai, India and Sigma Aldrich Chemical Co (USA) and used without further purification. Pre-coated silica gel 60 F₂₅₄ plates were used for thin-layer chromatography (TLC) and the spots on the TLC plates were visualized by UV lamp (254 nm). The benzothiazepines (**22-41**) were purified by recrystallization using ethanol. Melting points were determined on Boetius melting point apparatus in open capillary tubes and were uncorrected. FT-IR spectra were recorded on Bruker Vertex 80v spectrometer using potassium bromide discs and the absorption band values are given in cm⁻¹. Proton and carbon magnetic resonance (¹H NMR and ¹³C NMR) were recorded on Bruker AMX 400 NMR spectrophotometer using Tetramethyl silane (TMS) as internal standard and the chemical shift values are given in parts per million (ppm) relative to TMS. Mass spectra (MS) were recorded on Agilent 6100 QQQ ESI mass spectrophotometer by electron spray ionization technique.

2.2. Experimental


2.2.1 General procedure for the synthesis of chalcones (**2-21**)

To a mixture of 2-acetyl-5-chloropyrazine (0.001 M) and the appropriate aryl or heteroaryl aldehyde (0.001 M) was stirred in ethanol (7.5 mL) and to it aqueous solution of NaOH (40 %, 7.5 mL) was added. The mixture was kept for 24 h and it was acidified with 1:1 mixture of

hydrochloric acid and water, then it was filtered under vacuum and the product was washed with water (Vegesna et al., 2017).

2.2.2 General procedure for the synthesis of chloropyrazine conjugated 1,5-benzothiazepines (**22-41**)

To a mixture of 1 mmol of chalcones (**2-21**) and 1.5 mmol of 2-Aminothiophenol in dry methanol (50 mL), a catalytic amount of piperidine was added. The mixture was refluxed for 8 h. After cooling, the solid product separated was collected and washed with diethyl ether (2 x 50 mL) and cold methanol (2 x 50 mL). The crude solid was recrystallized from ethanol (Shaik et al., 2020).



Scheme 1. Synthesis of target compounds (**2-21**) and (**22-41**): (a) Ethanol, NaOH, room temperature (b) 2-Aminothiophenol, Piperidine/Ethanol, reflux

2.2.1.1. 2,3-Dihydro-2-phenyl-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (**22**): FT-IR (KBr): 1584 (C=N), 1510 (C=C), 1395 (C-N), 663 (C-S), 879 (C-Cl), 3032 (Ar C-H); ¹H

NMR (400 MHz, CDCl₃): 5.11 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.52 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.21 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.19-8.22 (11H, Ar-H); ¹³H NMR (100 MHz, CDCl₃): 50.15 (C-2), 40.24 (C-3), 164.66 (C-4), 122.54, 126.44, 127.51, 127.81, 128.80, 133.31, 141.72, 144.46, 146.73, 150.32 and 151.45 (Ar-C's); MS (m/z): [M⁺], 351.15, [M+2], 353.15.

2.2.1.2. *2,3-Dihydro-2-(4-chlorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (23)*: FT-IR (KBr): 1590 (C=N), 1505 (C=C), 1395 (C-N), 660 (C-S), 841 (C-Cl), 3021 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.23 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.54 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.29 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.15-8.01 (10H, Ar-H).

2.2.1.3. *2,3-Dihydro-2-(4-fluorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (24)*: FT-IR (KBr): 1593 (C=N), 1512 (C=C), 1397 (C-N), 665 (C-S), 922 (C-Cl), 921 (C-F), 3070 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.31 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.81 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.37 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.76-8.85 (10H, Ar-H).

2.2.1.4. *2,3-Dihydro-2-(4-nitrophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (25)*: FT-IR (KBr): 1591 (C=N), 1512 (C=C), 1369 (C-N), 681 (C-S), 854 (C-Cl), 3059 (Ar C-H), 1558 (N=O, asymmetric), 1341 (N=O, symmetric); ¹H NMR (400 MHz, CDCl₃): 5.33 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 4.01 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.73 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.70-8.56 (10H, Ar-H).

2.2.1.5. *2,3-Dihydro-2-(2,4-fluorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (26)*: FT-IR (KBr): 1602 (C=N), 1518 (C=C), 1403 (C-N), 691 (C-S), 856 (C-Cl), 919 (C-F), 3060 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.45 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.76 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.51 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.66-8.61 (9H, Ar-H).

2.2.1.6. *2,3-Dihydro-2-(2,4-dichlorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (27)*: FT-IR (KBr): 1592 (C=N), 1526 (C=C), 1382 (C-N), 688 (C-S), 945 (C-Cl), 3020 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.43 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.99 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.62 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.90-8.96 (9H, Ar-H).

2.2.1.7. *2,3-Dihydro-2-(4-hydroxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (28)*: FT-IR (KBr): 1596 (C=N), 1518 (C=C), 1388 (C-N), 667 (C-S), 915 (C-Cl), 3452 (Ar-OH), 3024 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 4.72 (s, 1H, Ar-OH), 5.23 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.51 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.28 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.20-8.19 (10H, Ar-H).

2.2.1.8. *2,3-Dihydro-2-(4-methylphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (29)*: FT-IR (KBr): 1588 (C=N), 1516 (C=C), 1390 (C-N), 678 (C-S), 888 (C-Cl), 2935 (Alkyl C-H), 3022 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 2.38 (s, 3H, Ar-CH₃), 4.95 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.32 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.11 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.10-8.09 (10H, Ar-H).

2.2.1.9. *2,3-Dihydro-2-(4-methoxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (30)*: FT-IR (KBr): 1586 (C=N), 1519 (C=C), 1395 (C-N), 666 (C-S), 912 (C-Cl), 1219 (-O-CH₃), 3045 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 3.88 (s, 3H, Ar-OCH₃), 5.10 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.53 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.26 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 6.52-7.83 (10H, Ar-H).

2.2.1.10.

2,3-Dihydro-2-(3-methoxy-4-hydroxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (31): FT-IR (KBr): 1600 (C=N), 1515 (C=C), 1398 (C-N), 665 (C-S), 896 (C-Cl), 1222 (-O-CH₃), 3420 (Ar-OH), 3045 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 3.80 (s, 3H, Ar-OCH₃), 4.91 (s, 1H, Ar-OH), 4.99 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.32 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.06 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 6.69-8.10 (9H, Ar-H).

2.2.1.11.

2,3-Dihydro-2-(4-dimethylaminophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (32): FT-IR (KBr): 1651 (C=N), 1519 (C=C), 1391 (C-N), 671 (C-S), 910 (C-Cl), 1205 (-N(CH₃)₂), 3048 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 3.18 (s, 6H, -N(CH₃)₂), 5.28 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.60 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.41 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 6.65-8.07 (10H, Ar-H).

2.2.1.12.

2,3-Dihydro-2-(3,4-dimethoxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (33): FT-IR (KBr): 1615 (C=N), 1512 (C=C), 1329 (C-N), 682 (C-S), 1229 (-O-CH₃), 3095 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 3.83 (s, 3H, Ar-OCH₃), 3.88 (s, 3H, Ar-OCH₃), 5.01

(dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.31 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.11 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 6.85-8.06 (9H, Ar-H).

2.2.1.13.

2,3-Dihydro-2-(3,4,5-trimethoxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (34): FT-IR (KBr): 1599 (C=N), 1508 (C=C), 1371 (C-N), 1226 (-O-CH₃), 694 (C-S), 901 (C-Cl), 3014 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 3.70 (s, 6H, 2x Ar-OCH₃), 3.95 (s, 3H, Ar-OCH₃), 5.05 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.29 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.10 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 6.78-8.12 (10H, Ar-H).

2.2.1.14. 2,3-Dihydro-2-(pyridin-2-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (35): FT-IR (KBr): 1595 (C=N), 1517 (C=C), 1396 (C-N), 672 (C-S), 886 (C-Cl), 1136 (-O-CH₃), 3025 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.03 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.29 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.12 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 6.85-8.14 (10H, Ar-H).

2.2.1.15. 2,3-Dihydro-2-(pyridin-3-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (36): FT-IR (KBr): 1602 (C=N), 1504 (C=C), 1387 (C-N), 676 (C-S), 865 (C-Cl), 3031 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.51 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.77 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.56 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.45-8.49 (10H, Ar-H).

2.2.1.16. 2,3-Dihydro-2-(pyridin-4-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (37): FT-IR (KBr): 1610 (C=N), 1517 (C=C), 1391 (C-N), 692 (C-S), 859 (C-Cl), 3171 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.11 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.49 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.16 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.18-8.28 (10H, Ar-H).

2.2.1.17. 2,3-Dihydro-2-(4-thienyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (38): FT-IR (KBr): 1595 (C=N), 1525 (C=C), 1395 (C-N), 671 (C-S), 891 (C-Cl), 3012 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.29 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.72 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), 3.49 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b), 7.10-8.12 (9H, Ar-H).

2.2.1.18. 2,3-Dihydro-2-(2-furfuryl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (39): FT-IR (KBr): 1583 (C=N), 1511 (C=C), 1385 (C-N), 699 (C-S), 875 (C-Cl), 3129 (Ar C-H); ¹H NMR (400 MHz, CDCl₃): 5.58 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.55 (dd, $J_{3a,3b}$

= 14.4 Hz, $J_{3a,2}$ = 9.9 Hz, 1H, C3-H-3a), 3.34 (t, $J_{3b,3a}$ = $J_{3b,2}$ = 12.9 Hz, 1H, C3-H-3b), 6.95-8.11 (9H, Ar-H).

2.2.1.19. *2,3-Dihydro-2-(2-pyrrolyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (40)*: FT-IR (KBr): 1592 (C=N), 1527 (C=C), 1399 (C-N), 682 (C-S), 917 (C-Cl), 3321 (N-H), 3011 (Ar C-H); ^1H NMR (400 MHz, CDCl_3): 10.09 (s, 1H, -NH), 5.25 (dd, $J_{2,3a}$ = 5.1 Hz, $J_{2,3b}$ = 12 Hz, 1H, C2-H), 3.56 (dd, $J_{3a,3b}$ = 14.4 Hz, $J_{3a,2}$ = 9.9 Hz, 1H, C3-H-3a), 3.42 (t, $J_{3b,3a}$ = $J_{3b,2}$ = 12.9 Hz, 1H, C3-H-3b), 6.87-8.15 (9H, Ar-H).

2.2.1.20. *2,3-Dihydro-2-(pyrazol-5-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (41)*: FT-IR (KBr): 1588 (C=N), 1522 (C=C), 1387 (C-N), 669 (C-S), 911 (C-Cl), 3326 (N-H), 3051 (Ar C-H); ^1H NMR (400 MHz, CDCl_3): 10.25 (s, 1H, N-H), 5.51 (dd, $J_{2,3a}$ = 5.1 Hz, $J_{2,3b}$ = 12 Hz, 1H, C2-H), 3.54 (dd, $J_{3a,3b}$ = 14.4 Hz, $J_{3a,2}$ = 9.9 Hz, 1H, C3-H-3a), 3.21 (t, $J_{3b,3a}$ = $J_{3b,2}$ = 12.9 Hz, 1H, C3-H-3b), 7.28-8.31 (8H, Ar-H).

2.3. Antimicrobial activity

The antimicrobial (antibacterial and antifungal) activities of the novel chloropyrazine clubbed benzothiazepines (**22-41**) was evaluated against selected bacterial and fungal strains using standard experimental procedures as described in the literature (Vegesna et al., 2017). The standard strains were procured from the American Type Culture Collection (ATCC) and Gene Bank, Institute of Microbial Technology, Chandigarh, India. The bacterial strains selected for the study were *Bacillus subtilis* (ATCC-60511), *Staphylococcus aureus* (ATCC-11632), *Escherichia coli* (ATCC-10536), *Pseudomonas aeruginosa* (ATCC-10145) whereas the fungal strains include *Aspergillus niger* (ATCC-6275) and *Candida tropicalis* (ATCC-1369) respectively. Ciprofloxacin was used as positive control for antibacterial studies and fluconazole for antifungal activity. Antibacterial activity was performed using nutrient agar medium whereas Potato Dextrose-Agar medium was used for antifungal testing. 2.048 mg of each test compound was taken in vials separately. Then 2 mL of methanol was added. Thus, a solution with a concentration of 1.024 mg/mL was obtained. All the experiments were carried out in triplicate and the results are presented as the mean of three independent experiments. The microbial strains were grown at 37 °C in their respective nutrient medium and diluted in sterile nutrient broth medium to get a suspension containing 10^7 cells/mL and this suspension was used as the inoculum. All the test tubes were incubated

for 18 h at 37 °C. A similar experiment with inoculum, medium and methanol without compound was furthermore performed to confirm that there is no inhibitory effect of methanol used for the dilutions. The test tube number in which the first sign of the growth of the organism observed was noted using a spectrophotometer. The MIC was determined for all the compounds by taking that concentration used in the test tube number just before the test tube number where the first sign of growth observed (Kasetti et al., 2020).

2.4. Antitubercular activity

Chalcone precursors (1-21) and conjugated 1,5-benzothiazepine derivatives (**22-41**) were evaluated for antitubercular activity using the same procedure which we described in our previous paper [Kishore et al., 2017, Lokesh et al., 2019, Palleepati et al., 2019] on *Mycobacterium tuberculosis* H₃₇Rv strain (procured from National Institute of Tuberculosis, Chennai, India) using pyrazinamide (Sigma-Aldrich, USA) as reference drug. Broth dilution assay was employed to determine the minimum inhibitory concentration (MIC) of each compound. All the test compounds were dissolved separately in dimethyl sulfoxide (DMSO, (Merck Life Sciences Private Limited, Mumbai, India) and then diluted twice at the required concentration. A frozen culture in Middle brook 7H9 broth added with 10% albumin-dextrose-catalase and 0.2% glycerol (Himedia, Mumbai, India) was melted and diluted in broth to 10⁵ cfu mL⁻¹ (colony forming unit/mL) dilutions. The final concentration of DMSO in the assay medium was 1.3%. Then, each U-tube was inoculated with 0.05 mL of standardized culture and incubated at 37°C for 21 days. The growth in the U-tubes was compared with visibility in opposition to a negative control (without drug and inoculum), positive control (without drug), and with standard pyrazinamide. The MIC values obtained in µg/mL were converted into µM for the standard drug pyrazinamide and the target compounds (**2-41**) in order allow comparison in molecular level.

2.5. Cytotoxic activities

DU-145 (prostate cancer) and normal liver (L02) cell lines were obtained from National Centre for Cell Science (NCCS), Pune, India. DMEM (Dulbeccos Modified Eagles Medium), MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], Trypsin, EDTA were purchased from Sigma chemicals (St.Louis,MO). Fetal bovine serum (FBS) was purchased from Arrow Labs, 96 well flat bottom tissue culture plates were purchased from Tarson. The *in vitro* cytotoxic activity was performed for both chalcones (**2-21**) and benzothiazepines (**22-41**) on prostate cancer cell lines (DU-145) by Mosmann's MTT assay (Mosmann, 1983) and their IC₅₀ values were determined. The cytotoxic activity of the target

compounds was compared with the standard drug methotrexate (Mtx). In principle, the assay is based on the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to formazan (blue-purple colored) product, due to the action of mitochondrial reductase enzyme inside the living cells. DU-145 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) at 37°C and humidified at 5% CO₂. The test compounds (**2-41**) were dissolved in 0.1% DMSO to make their stock solutions. From these stock solutions, different dilutions of the compounds were made with sterile water to attain the required final concentrations. Briefly, the cells were placed on 96-well plates at 100 µL total volume with a density of 1×10^4 cells per well and were allowed to adhere for 24 h. Later, the medium was replaced with fresh media containing different dilutions of the test compounds and allowed to incubate for another 48 h at 37°C in DMEM with 10% fetal bovine serum (FBS) medium. Afterwards, the medium was replaced with 90 µL of fresh DMEM without FBS. The wells were treated with 10 µL of MTT reagent (5 mg/mL of stock solution in DMEM without FBS) and incubated at 37°C for 3-4 h. The formed blue crystals of formazan were dissolved in 200 µL of DMSO, and the optical density was determined at 570 nm using micro plate reader. Assay was carried out in triplicate for three independent experiments. The results had good reproducibility between replicate wells with standard errors below 10%. The cytotoxic activity results measured as IC₅₀ values in µg/mL were converted into µM. All the compounds were also evaluated for their cytotoxicity on normal human liver cell lines (L02) to determine their toxicity by using the identical protocol as described above.


3. Results and discussion

3.1. Chemistry

Choloropyrazine based chalcones (**2-21**) and conjugated 1,5-benzothiazepines (**22-41**) described here were synthesized following the synthetic routes outlined in **Scheme 1**. To prepare chalcones **2-21**, 2-acetyl-5-chloropyrazine was treated with substituted aromatic and heteroaromatic aldehydes in ethanol under basic conditions to obtain yields between 55%-97% (Vegesna et al., 2017). Intermediates **2-21** were refluxed with 2-aminothiophenol to obtain target benzothiazepines **22-41** with yields between 58%-95% (**Table 1**). The compound **22** was analyzed for molecular formula C₁₉H₁₄ClN₃S, m.p. 166-168°C, well supported by a M⁺ peak at m/z 351.85 and also a satellite peak at m/z 353.85 with 3:1 intensity in its electron spray ionization mass spectrum. The FT-IR spectrum (cm⁻¹) of the compound **22** showed the characteristic bands at 1584 (C=N), 1510 (C=C), 1395 (C-N), 663 (C-S), 844 (C-Cl), and 3032 (Ar C-H). The ¹H NMR spectrum of compound **22** showed three

characteristic peaks of C2-H and C3-CH₂ protons of 1,5-benzothiazepine ring at 5.11 (dd, $J_{2,3a} = 5.1$ Hz, $J_{2,3b} = 12$ Hz, 1H, C2-H), 3.52 (dd, $J_{3a,3b} = 14.4$ Hz, $J_{3a,2} = 9.9$ Hz, 1H, C3-H-3a), and 3.21 (t, $J_{3b,3a} = J_{3b,2} = 12.9$ Hz, 1H, C3-H-3b). The spectrum also accounted for the other twelve aromatic protons in between δ 7.19-8.22. The ¹³C NMR spectrum of compound **22** accounted for all the carbons whose resonance appeared at the following δ values: 50.15 (C-2), 40.24 (C-3), 164.66 (C-4), 122.54, 126.44, 127.51, 127.81, 128.80, 133.31, 141.72, 144.46, 146.73, 150.32 and 151.45 (Ar-C's). The values are consistent with the proposed structure for the compound. Based on the above spectral data and elemental analysis, the structure of compound **22** was confirmed as 2,3-dihydro-2-phenyl-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (**Fig. 4**). Similarly, other **19** compounds exhibited their characteristic spectral features in their FT-IR and ¹H NMR spectra. The general structures and physicochemical properties of compounds **22-41** are shown in **Table 1**.

Table 1. Chemical structures and physicochemical properties of compounds **22-41**.



Entry	Ar	% Yield	m.p. °C
22	phenyl	90	166-168
23	4-chlorophenyl	95	155-157
24	4-fluorophenyl	92	171-173
25	4-nitrophenyl	83	185-187
26	2,4-difluorophenyl	79	121-123
27	2,4-dichlorophenyl	88	133-135
28	4-hydroxyphenyl	63	196-198
29	4-methylphenyl	79	148-150
30	4-methoxyphenyl	66	205-207
31	3-methoxy-4-hydroxyphenyl	73	252-254
32	4-dimethylaminophenyl	91	175-177
33	3,4-dimethoxyphenyl	81	166-168
34	3,4,5-trimethoxyphenyl	75	210-212
35	2-pyridinyl	65	211-213
36	3-pyridinyl	58	118-120
37	4-pyridinyl	66	131-133
38	2-thienyl	69	150-152
39	2-furfuryl	80	142-144
40	2-pyrrolyl	75	175-177
41	5-pyrazolyl	82	232-236


3.2. Antimicrobial activity

All the compounds synthesized through this study were evaluated for their antimicrobial, antitubercular, and cytotoxic activities employing standard protocols. The compounds were classified into three different categories based on their structural features. Physicochemical properties modulated were based on the “R” group. Electron withdrawing or donating groups on phenyl ring (**Tables 2-5**) were either substituted at para position (**3-5, 8-10 & 12; 23-25, 28-30, and 32**), ortho and para positions (**6, 7, 26 & 27**), or meta & para positions (**11, 13, 14, 31, 33 and 34**). Bioisosteric substitution of phenyl ring with pyridyl, thienyl, furfuryl, pyrrolyl, and pyrazolyl systems resulted in compounds **15-21** and **35-41** as chalcone and benzothiazepine derivatives.

3.2.1. Antibacterial activity

Compounds **22-41** were evaluated for their antibacterial activity (**Table 2**) against *Bacillus subtilis*, *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa* using ciprofloxacin as standard.

Table 2. Antibacterial activity of benzothiazepines **22-41** (expressed as MIC in μM).



Entry	Ar	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>P. aeruginosa</i>
22	phenyl	>200	>200	>200	>200
23	4-chlorophenyl	82.83	82.83	82.83	82.83
24	4-fluorophenyl	86.52	86.52	86.52	86.52
25	4-nitrophenyl	80.63	80.63	80.63	80.63
26	2,4-difluorophenyl	41.25	41.25	41.25	41.25
27	2,4-dichlorophenyl	38.02	38.02	38.02	38.02
28	4-hydroxyphenyl	>200	>200	>200	>200
29	4-methylphenyl	>200	174.92	>200	>200
30	4-methoxyphenyl	>200	>200	>200	>200
31	3-methoxy-4-hydroxyphenyl	>200	>200	>200	>200
32	4-dimethylaminophenyl	162.05	>200	>200	>200
33	3,4-dimethoxyphenyl	>200	>200	>200	>200
34	3,4,5-trimethoxyphenyl	144.81	144.81	72.40	144.81
35	2-pyridinyl	>200	>200	>200	>200
36	3-pyridinyl	181.38	>200	181.38	>200
37	4-pyridinyl	181.38	181.38	181.38	181.38
38	2-thienyl	178.83	>200	>200	178.83
39	2-furfuryl	>200	>200	>200	>200
40	2-pyrrolyl	>200	>200	>200	>200

41	5-pyrazolyl	>200	>200	>200	>200
Ciprofloxacin		145.71	145.71	72.85	72.85

The benzothiazepine series (**22-41**) (**Table 2**) overall antibacterial activity ranged from 38->200 μ M. For compounds **22-25**, **28-30**, and **32**, the para position was substituted with either H (**22**), Cl (**23**), F (**24**), NO₂ (**25**), OH (**28**), CH₃ (**29**), OCH₃ (**30**), and N(CH₃)₂ (**32**). Compound **22** with H substituent showed inactivity with MICs >200 μ M against four bacterial species. Replacing H substituent (**22**) with electron withdrawing substituents chlorine (Cl) (**23**) fluorine (F) (**24**), or nitro (NO₂) (**25**) resulted in MICs between 80-86 μ M suggesting an improvement in the activity against four bacterial species over compound **22**. Changing the para position of electron withdrawing to electron donating groups OH (**28**), CH₃ (**29**), OCH₃ (**30**), and N(CH₃)₂ (**32**), a trend similar to chalcones **8-10** and **12** (Vegnesa et al., 2017) was observed causing a significant loss in potency with MICs between 162->200 μ M indicating that electron withdrawing groups are favored over donating groups at the para position of the phenyl ring.

Based on our data obtained from compounds **23-25**, **28-30**, and **32**, we decided to synthesize few compounds having electron withdrawing and electron donating groups at ortho/para and meta/positions. As seen in compounds **26** and **27**, they showed 2-fold improvement in the antibacterial activity (38.02-41.25 μ M) over the compounds **23-25** with electron withdrawing groups (**23-25**; 80.63-86.52 μ M), the most active being compound **27** (MIC 38.02 μ M). However, in case of disubstituted chalcones with electron donating groups **31** and **33**, it resulted in MICs between >200 μ M, suggesting loss of activity similar to compounds **28-30**.


Among the bioisosteres (**35-41**), there was no improvement in the activity in comparison to the standard ciprofloxacin. The MICs varied between 178- >200 μ M. The most potent among all benzothiazepines was compound **27** (MIC 38.02 μ M) having two- to four-fold improvement in activity over ciprofloxacin against four bacterial species. Overall, chalcones (Vegnesa et al., 2017) fared better over benzothiazepine derivatives. Comparing between the two series, it can be inferred that in chalcone and benzothiazepine series, physicochemical property was modulated by electron withdrawing groups in ortho/para positions thereby improving the antibacterial activity.

3.2.2. Antifungal activity

The antifungal activity (**Table 3**) of benzothiazepine series (**22-41**) ranged from 19->200 μ M. Compound **22** with H substituent showed the lowest antibacterial activity with MIC of 181 μ M against two fungal species in comparison to compounds **23-34**. Replacing H substituent (**22**) with electron withdrawing substituents chlorine (Cl) (**23**), fluorine (F) (**24**),

or nitro (NO₂) (**25**) resulted in MICs between 40-43 µM suggesting 4.2-4.5-fold improvement in the activity against two fungal species, respectively, over compound **22**. Changing the para position from electron withdrawing to electron donating groups OH (**28**), CH₃ (**29**), OCH₃ (**30**), and N(CH₃)₂ (**32**) resulted in a trend similar to chalcones **8-10** and **12** causing a significant drop in the activity with MICs between 162-174 µM against *A. niger* and 173.98- >200 µM against *C. tropicalis*.

Table 3. Antifungal activities of benzothiazepines (**22-41**) (expressed as MIC in µM).



Entry	Ar	<i>A. niger</i>	<i>C. tropicalis</i>
22	phenyl	181.91	181.91
23	4-chlorophenyl	41.41	41.41
24	4-fluorophenyl	43.26	43.26
25	4-nitrophenyl	40.31	40.31
26	2,4-difluorophenyl	20.62	20.62
27	2,4-dichlorophenyl	19.01	19.01
28	4-hydroxyphenyl	173.98	173.98
29	4-methylphenyl	174.92	174.92
30	4-methoxyphenyl	167.59	>200
31	3-methoxy-4-hydroxyphenyl	>200	>200
32	4-dimethylaminophenyl	162.05	>200
33	3,4-dimethoxyphenyl	38.84	155.37
34	3,4,5-trimethoxyphenyl	36.20	36.20
35	2-pyridinyl	90.69	45.34
36	3-pyridinyl	45.34	45.34
37	4-pyridinyl	>200	90.69
38	2-thienyl	44.70	44.70
39	2-furfuryl	93.61	187.23
40	2-pyrrolyl	>200	187.77
41	5-pyrazolyl	187.23	187.23
Fluconazole		84.14	63.10

Electron withdrawing groups at ortho/para positions as seen in compounds **26** and **27** showed two-fold improvement in the antibacterial activity (19.01-20.62 µM) over compounds **23-25** with electron withdrawing groups (**23-24**; 40.31-43.26 µM). Compounds **26** & **27** (MICs 20.62 & 19.01 µM) had similar antifungal activity. However, in case of electron donating groups **31** (meta/para) and **33** (meta/para), it resulted in MICs between 38.84- >200 µM with

compound **33** (MIC 38.84 μ M) having better activity against *A. niger* over compound **30** (MIC 167.59 μ M vs *A. niger*).


The MICs of bioisosteres **35-41** varied between 44-751 μ M. Among the six-membered pyridine ring containing bioisosteres (**35-37**), compound **36** showed the best activity of 45.34 μ M. Although among five-membered heterocycles, the 2-thienyl containing benzothiazepine **38** showed the best activity of 44.70 μ M; it was comparatively less than standard fluconazole. The most potent among all benzothiazepines identified was compound **27** (MIC 19.01 μ M) having three- to four-fold improvement in activity over fluconazole. Overall, benzothiazepines were found to have comparable activity with chalcones (Vegesna et al., 2017).

3.3. Antitubercular activity

Chalcone (**2**) with H substituent showed the modest antifungal activity with MIC 130.78 μ M against *M. tuberculosis* (**Table 4**). Replacing H substituent (**2**) with electron withdrawing substituents chlorine (Cl) (**3**) and fluorine (F) (**4**) resulted in MICs between 57-60 μ M suggesting nine-fold enhancement in the activity against two fungal species. Substitution of halogens with a nitro group **5** resulted in four-fold decrease in activity over **3** and **4**. It was observed that compounds **8, 9, 10, and 12** having electron donating groups caused a significant drop in the activity (MICs 116-491 μ M).

Having electron withdrawing groups at ortho and para position of phenyl ring resulted in further improvement in antitubercular activity by two-fold (**7** vs **3**, MICs 25.51 vs 57.32 μ M; **6** vs **4**, MICs 28.50 vs 60.91 μ M). Substituting meta and para position with electron donating groups (compounds **11** and **13**) showed modest activity (MICs 52-110 μ M), with compound **13** having better activity over compound **11**. Interestingly, substituting the para and the two meta positions with methoxy substituent **14** improved the activity to 23.89 μ M. Compound **14** was identified as the most potent of all the synthesized chalcones having 17-fold improved activity over pyrazinamide (MIC 412.76 μ M). The next in potency among the chalcone series was compound **7** having MIC of 25.51 μ M. Bioisoster-based chalcones **15-21** did not show any improvement in activity with MICs of 521-1095 μ M.

Table 4. Antitubercular activities of chalcones (**2-21**) and benzothiazepines (**22-41**) (expressed as MIC in μM).



#	Ar	MIC values (μM) of <i>M. tuberculosis</i> H37Rv	#	MIC values (μM) of <i>M. tuberculosis</i> H37Rv
2	phenyl	130.78	22	181.89
3	4-chlorophenyl	57.32	23	82.83
4	4-fluorophenyl	60.91	24	43.26
5	4-nitrophenyl	220.93	25	322.54
6	2,4-difluorophenyl	28.50	26	41.25
7	2,4-dichlorophenyl	25.51	27	38.02
8	4-hydroxyphenyl	491.02	28	>500
9	4-methylphenyl	123.69	29	174.92
10	4-methoxyphenyl	116.49	30	167.59
11	3-methoxy-4-hydroxyphenyl	110.07	31	160.85
12	4-dimethylaminophenyl	444.83	32	324.11
13	3,4-dimethoxyphenyl	52.50	33	38.84
14	3,4,5-trimethoxyphenyl	23.89	34	18.10
15	2-pyridinyl	>500	35	>500
16	3-pyridinyl	>500	36	>500
17	4-pyridinyl	>500	37	>500
18	2-thienyl	>500	38	>500
19	2-furfuryl	>500	39	>500
20	2-pyrrolyl	>500	40	>500
21	5-pyrazolyl	>500	41	>500
Pyrazinamide		412.76		

The benzothiazepine series (**22-41**) fared slightly better than the chalcones (**Table 4**). The overall antitubercular activity ranged from 18-1497 μM . Compound **22** with H substituent showed the modest antibacterial activity with MIC of 181.89 μM . Substituting H substituent (**22**) with electron withdrawing substituents chlorine (Cl) (**23**) and fluorine (F) (**24**) resulted in MICs between 43-82 μM , suggesting two- to + improvement in the activity against *M. tuberculosis* over compound **22**. However, inserting a 4-nitro (**25**) substituent surprisingly proved to be deleterious for the activity in comparison to compounds **23** and **24**. This trend was found to be similar to chalcones **3**, **4** in comparison to **5**. Changing the para position from electron withdrawing to electron donating groups OH (**28**), CH₃ (**29**), OCH₃ (**30**), and N(CH₃)₂ (**32**) resulted in attenuation in activity with MICs between 167- >500 μM , which highlights the importance of electron withdrawing group on the potency.


Electron withdrawing groups at ortho/para positions as seen in compounds **26** and **27** showed either similar or two-fold improvement in the antitubercular activity (38.02-41.25 μ M) over the compounds **23-25** with electron withdrawing groups (**23-24**; 43.26-82.83 μ M), the most active being compound **27** (MIC 38.02 μ M). Additionally, in case of electron donating groups **31** (meta/para), **33** (meta/para), it resulted in MICs between 38.84-160.85 μ M, with compound **33** having 4.3-fold better activity over compound **30** (MIC 167.59 μ M). Interestingly, compound **34** having three methoxy groups at positions 3, 4, and 5 on the phenyl ring resulted in two-fold improvement in activity over compound **33**, a trend found similar in chalcones (**14** vs **13**).

Introducing bioisosteric replacement for phenyl ring did not show any improvement in MICs as compounds **35-41** displayed inactivity with MICs >500 μ M. The activity trend of benzothiazepines were similar to chalcones (**27** vs **7** and **34** vs **14**). The most potent compound identified was **34** (MIC 18.01 μ M) having 23-fold improvement in activity over pyrazinamide. Overall, benzothiazepines were found to have antitubercular activity comparable with chalcones (**34** vs **14**; MICs 18.01 vs 23.89 μ M).

3.4. Cytotoxic activities

All the 40 compounds were evaluated for their cytotoxic activity against prostate cancer cell line, **DU-145**, employing MTT assay (**Table 5**). Among the chalcone series, compound **7** was found to be the most potent with IC_{50} 46.03 ± 1 μ M, whereas in benzothiazepine series, compound **41** had 1.3-fold better activity over **7** with the IC_{50} of 35.10 ± 2 μ M. The activity of these compounds was found to be 3-4-fold less than the standard, methotrexate ($IC_{50} = 11 \pm 1$ μ M). The compounds **4**, **6**, **26**, and **35** were next in activity with IC_{50} values 124.27 ± 1 , 121.18 ± 2 , 72.19 ± 2 and 51.01 ± 1 μ M, respectively. All the other compounds exhibited modest to inactivity with MICs ranging from 99.82 ± 2 to > 200 μ M. The structure activity relationship (SAR) features of chalcones and benzothiazepines indicated that electron withdrawing group (Cl) at ortho and para positions (**7**) and 5-pyrazolyl heterocyclic ring (**41**) played a key role in cytotoxic activity. The compounds were also tested against the human normal liver cells (**L02**) and were found to be less selective towards this cell type as the IC_{50} is beyond the highest concentration tested. (**Table 6**). A summary of the antibacterial, antifungal, antitubercular, and cytotoxic activities of chalcones (**2-21**) and benzothiazepines (**22-41**) is depicted in Fig. 4.


Table 5. Cytotoxic activity results of chalcones (**2-21**) and benzothiazepines (**22-41**) (IC₅₀ values in μM)



#	Ar	DU-145	#	DU-145
2	phenyl	>200	22	122.21 \pm 1
3	4-chlorophenyl	>200	23	119.08 \pm 2
4	4-fluorophenyl	124.27 \pm 1	24	156.82 \pm 2
5	4-nitrophenyl	>200	25	>200
6	2,4-difluorophenyl	121.18 \pm 2	26	72.19 \pm 2
7	2,4-dichlorophenyl	46.03 \pm 1	27	99.82 \pm 2
8	4-hydroxyphenyl	>200	28	>200
9	4-methylphenyl	>200	29	>200
10	4-methoxyphenyl	>200	30	>200
11	3-methoxy-4-hydroxyphenyl	>200	31	>200
12	4-dimethylaminophenyl	>200	32	121.54 \pm 2
13	3,4-dimethoxyphenyl	>200	33	>200
14	3,4,5-trimethoxyphenyl	>200	34	158.39 \pm 2
15	2-pyridinyl	>200	35	51.01 \pm 1
16	3-pyridinyl	>200	36	>200
17	4-pyridinyl	>200	37	181.38 \pm 2
18	2-thienyl	>200	38	>200
19	2-furfuryl	>200	39	>200
20	2-pyrrolyl	>200	40	>200
21	5-pyrazolyl	>200	41	35.10 \pm 2
Methotrexate		11 \pm 1		

Data presented as mean \pm SD (n=3). All the compounds and the standard dissolved in DMSO, diluted with culture medium containing 0.1% DMSO. The control cells were treated with culture medium containing 0.1% DMSO.

Table 6. Cytotoxic activity (IC₅₀ in µg/mL) of chalcones (2–21) and benzothiazepines (22–41).



Entry	Ar	L02	#	L02
2	phenyl	>50	22	>40
3	4-chlorophenyl	>50	23	>40
4	4-fluorophenyl	>50	24	>40
5	4-nitrophenyl	>50	25	>40
6	2,4-difluorophenyl	>50	26	>40
7	2,4-dichlorophenyl	>50	27	>40
8	4-hydroxyphenyl	>50	28	>40
9	4-methylphenyl	>50	29	>40
10	4-methoxyphenyl	>50	30	>40
11	3-methoxy-4-hydroxyphenyl	>50	31	>40
12	4-dimethylaminophenyl	>50	32	>40
13	3,4-dimethoxyphenyl	>50	33	>40
14	3,4,5-trimethoxyphenyl	>50	34	>40
15	2-pyridinyl	>50	35	>40
16	3-pyridinyl	>50	36	>40
17	4-pyridinyl	>50	37	>40
18	2-thienyl	>50	38	>40
19	2-furfuryl	>50	39	>40
20	2-pyrrolyl	>50	40	>40
21	5-pyrazolyl	>50	41	>40
Methotrexate		-		

Data presented as mean \pm SD (n=3). All the compounds and the standard dissolved in DMSO, diluted with culture medium containing 0.1% DMSO. The control cells were treated with culture medium containing 0.1% DMSO.




Figure 4. Summary of the antibacterial, antifungal, antitubercular, and cytotoxic activities of chalcones (**2-21**) and benzothiazepines (**22-41**).

4. Conclusions

In our ongoing projects on the synthesis of compounds with potential antimicrobial, antitubercular, and cytotoxic activities, we have here reported 20 new compounds bearing benzothiazepine nucleus and evaluated our 20 previously reported chalcones for antitubercular and cytotoxic activities. Biological data indicated that benzodiazepines

demonstrated excellent antifungal and antitubercular activities. It was observed that the electronic property (electron withdrawing and electron releasing) of the substituents on the phenyl ring was instrumental for the difference in the potency of the compounds. For instance, among benzothiazepines, electron withdrawing groups resulted in excellent antimicrobial and antifungal activity. Structure activity relationship studies of chalcones indicated that electronic properties did not play a key role for antitubercular activities as evident by compounds **7** and **14** whereas a similar phenomenon was observed for benzothiazepine **34**. None of the compounds showed any improvement in cytotoxic activity over the standard drug methotrexate. All the compounds were found to be relatively less selective towards the human normal liver cell line LO2. Further studies are under progress to assess the computational binding characteristics of chalcones and benzodiazepines, which can give a fair understanding of newer analogs.

Acknowledgments: The authors like to acknowledge Vignan Pharmacy College, Vadlamudi, Andhra Pradesh, India for providing the lab facilities and chemicals for this work. R.R.B would like to thank the Dean's office of College of Pharmacy and Health Sciences, Ajman University, UAE for their support in preparation of this manuscript.

Declaration of Competing Interest: The authors declare no conflict of interest.

References

- Abu-Hashem, A. A. & El-Shazly, M. 2018. Synthesis of new isoxazole-, pyridazine-, pyrimidopyrazines and their anti-inflammatory and analgesic activity. *Med. Chem.* 14, 356-371.
- Ambrozkiewicz, W., Kučerová-chlupáčová, M., Jand'ourek, O., Konečná, K., Paterová, P., Bárta, P., Vinšová, J., Doležal, M. & Zitko, J. 2020. 5-Alkylamino-N-phenylpyrazine-2-carboxamides: Design, Preparation, and Antimycobacterial Evaluation. *Molecules.* 25, 1561.
- Ameta, K., Rathore, N. S. & Kumar, B. 2012. Synthesis and in vitro anti breast cancer activity of some novel 1, 5-benzothiazepine derivatives. *J. Serb. Chem. Soc.* 77, 725-731.
- Aneesa, F., Ravindra, K. & Bhagavanraju, M. 2015. Design, Synthesis, Antimicrobial and Antiinflammatory Activity of N-Pyrazolyl Benzamide Derivatives. *Med. Chem.* 5, 521-527.
- Ansari, F. L., Iftikhar, F., Mirza, B., Basheer, M. & Rashid, U. 2008. Solid-phase synthesis and biological evaluation of a parallel library of 2, 3-dihydro-1, 5-benzothiazepines. *Bioorg. Med. Chem.* 16, 7691-7697.
- Arya, K. & Dandia, A. 2008. The expedient synthesis of 1, 5-benzothiazepines as a family of cytotoxic drugs. *Bioorg. Med. Chem. Lett.* 18, 114-119.
- Bariwal, J. B., Upadhyay, K. D., Manvar, A. T., Trivedi, J. C., Singh, J. S., Jain, K. S. & Shah, A. K. 2008. 1, 5-Benzothiazepine, a versatile pharmacophore: a review. *Eur. J. Med. Chem.* 43, 2279-2290.
- Bhaskar, R., Ladole, C., Salunkhe, N., Barabde, J. & Aswar, A. 2020. Synthesis, characterization and antimicrobial studies of novel ONO donor hydrazone Schiff base complexes with some Divalent Metal (II) ions. *Arab. J. Chem.* 13, 6559-6567.
- Bills, C. E., McDonald, J. & Spies, T. D. 1939. Antipellagric action of pyrazine-2, 3-dicarboxylic acid and pyrazine monocarboxylic acid. *South. Med. J.* 32, 793-795.
- Bouz, G., Juhas, M., Pausas Otero, L., Paredes De La Red, C., Jand'ourek, O., Konečná, K., Paterová, P., Kubíček, V., Janoušek, J. & Doležal, M. 2020. Substituted N-(pyrazin-2-yl) benzenesulfonamides; Synthesis, anti-infective evaluation, cytotoxicity, and in silico studies. *Molecules.* 25, 138.
- Cavalier, J.-F., Burton, M., De Tollenaere, C., Dussart, F., Marchand, C., Rees, J.-F. & Marchand-Brynaert, J. 2001. 2, 6-Diamino-3, 5-diaryl-1, 4-pyrazine derivatives as novel antioxidants. *Synthesis.* 2001, 0768-0772.
- Chaffman, M. & Brogden, R. N. 1985. Diltiazem. *Drugs.* 29, 387-454.
- De Wang, X., Li, T., Li, Y., Yuan, W. H. & Zhao, Y. Q. 2020. 2-Pyrazine-PPD, a novel dammarane derivative, showed anticancer activity by reactive oxygen species-mediate apoptosis and endoplasmic reticulum stress in gastric cancer cells. *Eur. J. Pharmacol.* 881, 173211.
- Deshmukh, R. N., Dengle, R. V. & Rashinkar, G. 2016. Synthesis and antibacterial evaluation of bis-[1, 5]-benzothiazepines. *J. Chem. Pharm. Res.* 8, 250-254.

- Di Santo, R. & Costi, R. 2005. 2H-Pyrrolo [3, 4-b][1, 5] benzothiazepine derivatives as potential inhibitors of HIV-1 reverse transcriptase. *Il Farmaco*. 60, 385-392.
- El-Bayouki, K. A. 2011. Synthesis, reactions, and biological activity of 1, 4-thiazepines and their fused aryl and heteroaryl derivatives: a review. *J. Sulfur. Chem.* 32, 623-690.
- El-Bayouki, K. A. 2013. Benzo [1, 5] thiazepine: Synthesis, reactions, spectroscopy, and applications. *Org. Chem. Int.* 2013.
- Etaiw, S. E. H., Marie, H. & Elsharqawy, F. A. 2020. Structure and characterization of organotin bimetallic supramolecular coordination polymers based on copper cyanide building blocks and pyrazine or pyrazine-2-carboxylic acid as new promising anticancer agents. *Appl. Organomet. Chem.* e5831.
- Geyer III, H. M., Watzman, N. & Buckley, J. P. 1970. Effects of a tranquilizer and two antidepressants on learned and unlearned behaviors. *J. Pharm. Sci.* 59, 964-968.
- Gomtsyan, A. 2012. Heterocycles in drugs and drug discovery. *Chem. Heterocycl. Com.* 48, 7-10.
- Gudisela, M. R., Srinivasu, N., Mulakayala, C., Bommu, P., Rao, M. B. & Mulakayala, N. 2017. Design, synthesis and anticancer activity of N-(1-(4-(dibenzo [b, f][1, 4] thiazepin-11-yl) piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives. *Bioorg. Med. Chem. Lett.* 27, 4140-4145.
- Hopenwasser, J., Mozayani, A., Danielson, T. J., Harbin, J., Narula, H. S., Posey, D. H., Shrode, P. W., Wilson, S. K., Li, R. & Sanchez, L. A. 2004. Postmortem distribution of the novel antipsychotic drug quetiapine. *J. Anal. Toxicol.* 28, 264-268.
- Kasetti, A., Indrajeet, S., N. Ravindra & Shaik, A. B. 2020. Antimicrobial and antitubercular evaluation of some new 5-amino-1,3,4-thiadiazole-2-thiol derived Schiff bases, *Rev. Roum. Chim.* 65, 771-776.
- Kawakita, S., Kinoshita, M., Ishikawa, H., Kagoshima, T., Katori, R., Ishikawa, K. & Hirota, Y. 1991. Efficacy and safety of clentiazem in patients with essential hypertension: results of an early pilot test. *Clin. Cardiol.* 14, 53-60.
- Kendre, B. V., Landge, M. G. & Bhusare, S. R. 2019. Synthesis and biological evaluation of some novel pyrazole, isoxazole, benzoxazepine, benzothiazepine and benzodiazepine derivatives bearing an aryl sulfonate moiety as antimicrobial and anti-inflammatory agents. *Arab. J. Chem.* 12, 2091-2097.
- Kishor, P., Ramana, K. V. & Shaik, A. B. 2017. Antitubercular evaluation of isoxazolyl chalcones. *Res. J. Pharm. Biol. Chem. Sci.* 8, 730-735.
- Kucerova-Chlupacova, M., Dosedel, M., Kunes, J., Soltesova-Prnova, M., Majekova, M. & Stefek, M. 2018. Chalcones and their pyrazine analogs: synthesis, inhibition of aldose reductase, antioxidant activity, and molecular docking study. *Monatsh. Chem.* 149, 921-929.
- Kucerova-Chlupacova, M., Kunes, J., Buchta, V., Vejsova, M. & Opletalova, V. 2015. Novel pyrazine analogs of chalcones: synthesis and evaluation of their antifungal and antimycobacterial activity. *Molecules*, 20, 1104-1117.
- Kucerova-Chlupacova, M., Vyskovska-Tyllova, V., Richterova-Finkova, L., Kunes, J., Buchta, V., Vejsova, M., Paterova, P., Semelkova, L., Jandourek, O. & Opletalova, V. 2016. Novel halogenated pyrazine-based chalcones as potential antimicrobial drugs. *Molecules*, 21, 1421.

- Li, T., Zhang, J., Pan, J., Wu, Z., Hu, D. & Song, B. 2017. Design, synthesis, and antiviral activities of 1, 5-benzothiazepine derivatives containing pyridine moiety. *Eur. J. Med. Chem.* 125, 657-662.
- Lokesh, B., Prasad, Y. & Shaik, A. 2019a. Novel pyrimidine derivatives from 2, 5-dichloro-3-acetylthienyl chalcones as antifungal, antitubercular and cytotoxic agents: Design, synthesis, biological activity and docking study. *Asian. J. Chem.* 19, 310-321.
- Lokesh, B. V., Prasad, Y. R. & Shaik, A. B. 2019b. Synthesis, Biological evaluation and molecular docking studies of new pyrazolines as an antitubercular and cytotoxic agents. *Infect. Disord-Drug. Targets. (Formerly Current Drug Targets-Infectious Disorders)* 19, 310-321.
- Lokesh, B. V. S., Prasad, Y. R. & Shaik, A. B. 2017. Synthesis and biological activity of novel 2, 5-dichloro-3-acetylthiophene chalcone derivatives. *Indian. J. Pharm. Educ. Res.* 51, s679-s690.
- Mamedova, G., Mahmudova, A., Mamedov, S., Erden, Y., Taslimi, P., Tüzün, B., Tas, R., Farzaliyev, V., Sujayev, A. & Alwasel, S. H. 2019. Novel tribenzylaminobenzosulphonylimine based on their pyrazine and pyridazines: Synthesis, characterization, antidiabetic, anticancer, anticholinergic, and molecular docking studies. *Bioorg. Chem.* 93, 103313.
- Mangrolia, U. & Osborne, W. J. 2020. *Staphylococcus xylosus* VITURAJ10: Pyrrolo [1, 2 α] pyrazine-1, 4-dione, hexahydro-3-(2-methylpropyl)(PPDHMP) producing, potential probiotic strain with antibacterial and anticancer activity. *Microb. Pathog.* 104259.
- Minyar, P., Mokale, S. & Makhija, S. 2017. Design and synthesis of 5-methylpyrazine-2-carbohydrazide derivatives: A new anti-tubercular scaffold. *Arab. J. Chem.* 10, 41-46.
- Mor, S., Nagoria, S., Sindhu, S., Khatri, M., Sidhu, G. & Singh, V. 2017. Synthesis of indane-Based 1, 5-benzothiazepines derived from 3-Phenyl-2, 3-dihydro-1H-inden-1-one and antimicrobial studies thereof. *J. Heterocyclic. Chem.* 54, 3282-3293.
- Mosman, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods.* 65, 55-63.
- Nagao, T., Masanori, S., Iwasawa, Y., Takada, T., Ishida, R., Nakajima, H. & Kiyomoto, A. 1972. Studies on A New 1, 5-Benzothiazepine Derivative (CRD-401): III. Effects of Optical Isomers of CRD-401 on Smooth Muscle and Other Pharmacological Properties. *Jpn. J. Pharmacol.* 22, 467-478.
- Palleapati, K., Kancharlapalli, V. R. & Shaik, A. B. 2019. Synthesis, characterization and antitubercular evaluation of some new isoxazole appended 1-carboxamido-4, 5-dihydro-1H-pyrazoles. *J. Res. Pharm.* 23, 156-163.
- Pant, S., Jadon, R. & Bharti, A. K. 2018. Syntheses of 1, 5-Benzothiazepines: Part-50: 8-Substituted 2, 3/2, 5-dihydro-2, 4-diaryl-1, 5-benzothiazepines as Potential Antimicrobial Agents. *Asian. J. Chem.* 30, 767-770.
- Patel, B., Patel, R., Shaikh, H. M., Rajani, D. & Patel, M. 2016. Microwave Assisted Synthetic Approach of New Pyridine based Benzothiazepines: Their Antibacterial and Antifungal Activities. *Curr. Microw. Chem.* 3, 212-218.

- Patil, S. R., Sarkate, A. P., Karnik, K. S., Arsondkar, A., Patil, V., Sangshetti, J. N., Bobade, A. S. & Shinde, D. B. 2019. A facile synthesis of substituted 2-(5-(Benzylthio)-1, 3, 4-oxadiazol-2-yl) pyrazine using microwave irradiation and conventional method with antioxidant and anticancer activities. *J. Heterocyclic. Chem.* 56, 859-866.
- Saha, D., Jain, G. & Sharma, A. 2015. Benzothiazepines: chemistry of a privileged scaffold. *RSC. Adv.* 5, 70619-70639.
- Sekhar, B. C. 2014. Fused 1, 5-benzothiazepines from o-aminothiophenol and its derivatives as versatile synthons. *Acta. Chim. Slov.* 61, 651-680.
- Seo, Y., Lee, J. H., Park, S.-H., Namkung, W. & Kim, I. 2020. Expansion of chemical space based on a pyrrolo [1, 2-a] pyrazine core: Synthesis and its anticancer activity in prostate cancer and breast cancer cells. *Eur. J. Med. Chem.* 188, 111988.
- Servusova-Vanaskova, B., Jandourek, O., Paterova, P., Kordulakova, J., Plevakova, M., Kubicek, V., Kucera, R., Garaj, V., Naesens, L. & Kunes, J. 2015. Alkylamino derivatives of N-benzylpyrazine-2-carboxamide: synthesis and antimycobacterial evaluation. *MedChemComm.* 6, 1311-1317.
- Servusová, B., Vobicková, J., Paterová, P., Kubíček, V., Kuneš, J., Doležal, M. & ZITKO, J. 2013. Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides. *Bioorg. Med. Chem. Lett.* 23, 3589-3591.
- Shaik, A., Bhandare, R. R., Palleapati, K., Nissankararao, S., Kancharlapalli, V. & SHAIK, S. 2020a. Antimicrobial, antioxidant, and anticancer activities of some novel isoxazole ring containing chalcone and dihydropyrazole derivatives. *Molecules.* 25, 1047.
- Shaik, A. B., Prasad, Y. R., Shahanaaz, S. & Nissankararao, S. 2020b. Synthesis, Biological and Computational Evaluation of Novel 2, 3-dihydro-2-aryl-4-(4-isobutylphenyl)-1, 5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents. *Anti-Cancer. Agent. Med. Chem.* 20, 1115-1128.
- Shankar, B., Jalapathi, P., Valeru, A., Kumar, A. K., Saikrishna, B. & Rao Kudle, K. 2017. Synthesis and biological evaluation of new 2-(6-alkyl-pyrazin-2-yl)-1H-benz [d] imidazoles as potent anti-inflammatory and antioxidant agents. *Med. Chem. Res.* 26, 1835-1846.
- Sharma, A. K., Singh, G., Yadav, A. K. & Prakash, L. 1997. Improved method for the synthesis of new 1, 5-benzothiazepine derivatives as analogues of anticancer drugs. *Molecules.* 2, 129-134.
- Singh, I., Luxami, V. & Paul, K. 2020. Synthesis, cytotoxicity, pharmacokinetic profile, binding with DNA and BSA of new imidazo [1, 2-a] pyrazine-benzo [d] imidazol-5-yl hybrids. *Sci. Rep.* 10, 1-14.
- Stepanić, V., Matijašić, M., Horvat, T., Verbanac, D., Kučerová-Chlupáčová, M., Saso, L. & Žarković, N. 2019. Antioxidant Activities of Alkyl Substituted Pyrazine Derivatives of Chalcones—In Vitro and In Silico Study. *Antioxidants.* 8, 90.
- Tantawy, E. S., Amer, A. M., Mohamed, E. K., Abd Alla, M. M. & Nafie, M. S. 2020. Synthesis, characterization of some pyrazine derivatives as anti-cancer agents: In vitro and in Silico approaches. *J. Mol. Struct.* 128013.
- Tongxiu, X., Yan, W., Keqing, T., Ranran, W., Jingyi, Y. & Ping, Z. 2018. Synthesis and Antimicrobial Activity of 2-Substituted-phenyl-3-N,

- N-dimethylformamido)-4-methyl-1, 5-benzothiazepine. Chinese. J. Org. Chem. 38, 2731-2735.
- Upadhyay, K., Manvar, A., Rawal, K., Joshi, S., Trivedi, J., Chaniyara, R. & Shah, A. 2012. Evaluation of structurally diverse benzoazepines clubbed with coumarins as Mycobacterium tuberculosis agents. Chem. Biol. Drug. Des. 80, 1003-1008.
- Vegesna, S., Prasad, Y. R., & Afzal, B. S. 2017. Antimicrobial evaluation of some novel pyrazine based chalcones. IJAPS, 8(2), 11-18.
- Wang, R., Wang, Y., Bian, Y. & Zhang, P. 2020. Synthesis and Antifungal Activity of 1, 5-Benzothiazepines Containing 1, 2, 3-Triazole. Chinese. J. Org. Chem. 40, 398-407.
- Wu, L., Yang, X., Peng, Q. & Sun, G. 2017. Synthesis and anti-proliferative activity evaluation of novel benzo [d][1, 3] dioxoles-fused 1, 4-thiazepines. Eur. J. Med. Chem. 127, 599-605.
- Yan, W., Lingman, K., Ranran, W., Keqing, T. & Ping, Z. 2019. Synthesis and Antimicrobial Activity of C (3)-1, 2, 4-Triazolyl-1, 5-benzothiazepines. Chinese. J. Org. Chem. 39, 2663-2670.
- Yazdan, S. K., Sagar, D. V. & Shaik, A. B. 2015. Synthesis, Characterization and Biological Evaluation of Some New Pyrimidine Derivatives as Anti-Inflammatory and Cytotoxic Agents. Res. J. Pharm. Biol. Chem. Sci. 6, 173-185.
- Zaki, R. M., Kamal El-Dean, A. M., Radwan, S. M. & Abd Ul-Malik, M. A. 2018. A Convenient Synthesis, Reactions and Biological Activities of Some Novel Thieno [3, 2-e] pyrazolo [3, 4-b] pyrazine Compounds as Anti-microbial and Anti-inflammatory Agents. Curr. Org. Syn. 15, 863-871.
- Zitko, J., Mindlová, A., Valášek, O., Jand'ourek, O., Paterová, P., Janoušek, J., Konečná, K. & Doležal, M. 2018. Design, synthesis and evaluation of N-pyrazinylbenzamides as potential antimycobacterial agents. Molecules. 23, 2390.
- Zitko, J., Servusová-Vaňásková, B., Paterová, P., Navrátilová, L., Trejtnar, F., Kuneš, J. & Doležal, M. 2016. Design, synthesis and anti-mycobacterial evaluation of some new N-phenylpyrazine-2-carboxamides. Chem. Pap. 70, 649-657.
- Zitko, J., Servusová, B., Paterová, P., Mandíková, J., Kubíček, V., Kučera, R., Hrabcová, V., Kuneš, J., Soukup, O. & Doležal, M. 2013. Synthesis, antimycobacterial activity and *in vitro* cytotoxicity of 5-chloro-N-phenylpyrazine-2-carboxamides. Molecules. 18, 14807-14825.